आइसोनियाज़िड और मिथाइलफेनिडेट का इंटरैक्शन

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ].

Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.

Intervention Do not administer methylphenidate extended-release orally disintegrating tablets concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment.

Clinically Important Interactions with Methylphenidate Extended-Release Orally Disintegrating Tablets Table 1: Drugs Having Clinically Important Interactions with Methylphenidate Monoamine Oxidase Inhibitors (MAOI) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis.